| [1] |
BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263.
|
| [2] |
WANG S L, NIE F J, YIN Q Y, et al. Periodontitis promotes tumor growth and immune evasion via PD-1/PD-L1[J]. Cancer Immunol Immunother, 2024, 74(1): 22.
|
| [3] |
MOSEMAN J E, RASTOGI I, JEON D, et al. PD-1 blockade employed at the time CD8+ T cells are activated enhances their antitumor efficacy[J]. J Immunother Cancer, 2025, 13(5): e011145.
|
| [4] |
BISCHOFF P, TRINKS A, OBERMAYER B, et al. Single-cell RNA sequencing reveals distinct tumor microenvironmental patterns in lung adenocarcinoma[J]. Oncogene, 2021, 40(50): 6748-6758.
|
| [5] |
SONG P, LI W B, GUO L, et al. Identification and validation of a novel signature based on NK cell marker genes to predict prognosis and immunotherapy response in lung adenocarcinoma by integrated analysis of single-cell and bulk RNA-sequencing[J]. Front Immunol, 2022, 13: 850745.
|
| [6] |
MCLANE L M, ABDEL-HAKEEM M S, WHERRY E J. CD8 T cell exhaustion during chronic viral infection and cancer[J]. Annu Rev Immunol, 2019, 37: 457-495.
|
| [7] |
ZHU X H, LI K, LIU G C, et al. Microbial metabolite butyrate promotes anti-PD-1 antitumor efficacy by modulating T cell receptor signaling of cytotoxic CD8 T cell[J]. Gut Microbes, 2023, 15(2): 2249143.
|
| [8] |
MUTO S, ENTA A, MARUYA Y, et al. Wnt/β-catenin signaling and resistance to immune checkpoint inhibitors: from non-small-cell lung cancer to other cancers[J]. Biomedicines, 2023, 11(1): 190.
|
| [9] |
DU L Y, LEE J H, JIANG H F, et al. β-Catenin induces transcriptional expression of PD-L1 to promote glioblastoma immune evasion[J]. J Exp Med, 2020, 217(11): e20191115.
|
| [10] |
WANG J, ZHENG H, HE H, et al. TPX2 serves as a cancer susceptibility gene and is closely associated with the poor prognosis of endometrial cancer[J]. Genet Res, 2022, 2022: 5401106.
|
| [11] |
HU J R, HE Q, TIAN T, et al. Transmission of exosomal TPX2 promotes metastasis and resistance of NSCLC cells to docetaxel[J]. Onco Targets Ther, 2023, 16: 197-210.
|
| [12] |
LIU X L, WANG W Y, CHEN B, et al. Integrative analysis based on the cell cycle-related genes identifies TPX2 as a novel prognostic biomarker associated with tumor immunity in breast cancer[J]. Aging, 2024, 16(8): 7188-7216.
|
| [13] |
XU Y F, TAN X L, YANG Q, et al. Akkermansia muciniphila outer membrane protein regulates recruitment of CD8+ T cells in lung adenocarcinoma and through JAK-STAT signalling pathway[J]. Microb Biotechnol, 2024, 17(7): e14522.
|
| [14] |
LEE S Y, CHAE M K, YOON J S, et al. The effect of CHIR 99021, a glycogen synthase kinase-3β inhibitor, on transforming growth factor β-induced tenon fibrosis[J]. Invest Ophthalmol Vis Sci, 2021, 62(15): 25.
|
| [15] |
ANTONIA S J, VANSTEENKISTE J F, MOON E. Immunotherapy: beyond anti–PD-1 and anti-PD-L1 therapies[J]. Am Soc Clin Oncol Educ Book, 2016(36): e450-e458.
|
| [16] |
GENOVA C, DELLEPIANE C, CARREGA P, et al. Therapeutic implications of tumor microenvironment in lung cancer: focus on immune checkpoint blockade[J]. Front Immunol, 2022, 12: 799455.
|
| [17] |
YANG L, LI A T, YU W N, et al. Blockade of purine metabolism reverses macrophage immunosuppression and enhances anti-tumor immunity in non-small cell lung cancer[J]. Drug Resist Updat, 2025, 78: 101175.
|
| [18] |
SCHENKEL J M, FRASER K A, VEZYS V, et al. Sensing and alarm function of resident memory CD8⁺ T cells[J]. Nat Immunol, 2013, 14(5): 509-513.
|
| [19] |
MENARES E, GÁLVEZ-CANCINO F, CÁCERES-MORGADO P, et al. Tissue-resident memory CD8+ T cells amplify anti-tumor immunity by triggering antigen spreading through dendritic cells[J]. Nat Commun, 2019, 10(1): 4401.
|
| [20] |
WEN H, ZHANG P P, ZHAO J, et al. Metabolic alterations driven by LDHA in CD8+ T cells promote immune evasion and therapy resistance in NSCLC[J]. Sci Rep, 2025, 15(1): 24440.
|
| [21] |
DOLINA J S, VAN BRAECKEL-BUDIMIR N, THOMAS G D, et al. CD8+ T cell exhaustion in cancer[J]. Front Immunol, 2021, 12: 715234.
|
| [22] |
ZHOU F, WANG M, AIBAIDULA M, et al. TPX2 promotes metastasis and serves as a marker of poor prognosis in non-small cell lung cancer[J]. Med Sci Monit, 2020, 26: e925147.
|
| [23] |
ZHU M X, WANG X P, ZHANG Q, et al. Integrative analysis confirms TPX2 as a novel biomarker for clinical implication, tumor microenvironment, and immunotherapy response across human solid tumors[J]. Aging, 2024, 16(3): 2563-2590.
|
| [24] |
ZHANG Z G, LIU Z X, YAO Y, et al. Exploring the clinical significance of TPX2 in pancreatic cancer: from biomarker to immunotherapy[J]. Naunyn Schmiedeberg’s Arch Pharmacol, 2025, 398(6): 6843-6864.
|
| [25] |
DING L, ZHANG S H, CHEN S J, et al. Effect and mechanism of lentivirus-mediated silencing of TPX2 gene on proliferation and apoptosis of human hepatoma cells[J]. J Cell Biochem, 2019, 120(5): 8352-8358.
|
| [26] |
WANG D Y, WU S Y, HE J X, et al. FAT4 overexpression promotes antitumor immunity by regulating the β-catenin/STT3/PD-L1 axis in cervical cancer[J]. J Exp Clin Cancer Res, 2023, 42(1): 222.
|
| [27] |
SWEIS R F, SPRANGER S, BAO R Y, et al. Molecular drivers of the non-T-cell-inflamed tumor microenvironment in urothelial bladder cancer[J]. Cancer Immunol Res, 2016, 4(7): 563-568.
|
| [28] |
SRIDHARAN V, GJINI E, LIAO X Y, et al. Immune profiling of adenoid cystic carcinoma: PD-L2 expression and associations with tumor-infiltrating lymphocytes[J]. Cancer Immunol Res, 2016, 4(8): 679-687.
|
| [29] |
MUTO S, OZAKI Y, YAMAGUCHI H, et al. Tumor β-catenin expression is associated with immune evasion in non-small cell lung cancer with high tumor mutation burden[J]. Oncol Lett, 2021, 21(3): 203.
|
| [30] |
PEURA A, TURPIN R, LIU R X, et al. Soft matrix promotes immunosuppression in tumor-resident immune cells via COX-FGF2 signaling[J]. Nat Commun, 2025, 16(1): 4908.
|
| [31] |
XIONG J, HE L, CHAI X S, et al. YTHDF1 boosts the lactate accumulation to potentiate cervical cancer cells immune escape[J]. Cell Death Dis, 2024, 15(11): 843.
|